Novo Holdings, a holding and investment company, led a €45m Series B round in Acesion Pharma, a biotech company, with participation from Canaan, Alpha Wave and Global BioAccess Fund. “The high levels of investor interest and demand that we saw during this financing speak to the strong data we have generated, both on the novel mechanism of SK channel inhibition in general and the AP31969 compound specifically. This is a powerful endorsement for our team and the quality of our science. With the financing in hand, we are focused on progressing AP31969 into a phase 1 clinical trial later this year,” Anders Gaarsdal, Acesion CEO.